The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis

The Effects of Resveratrol Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02030977

Enrollment

Registered

2014-01-09

Start date

2012-06-30

Completion date

2013-03-31

Last updated

2014-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty Liver

Brief summary

To study the effects of Resveratrol supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Fatty Liver (NAfLD), 50 patients who referred to Gastrointestinal (GI) clinic with steatosis grade 1 or more will be randomly allocated to receive 1 Resveratrol capsules or placebos for 12 weeks; both groups will be advised to adherence our diet and exercise program too. At the first and the end of the intervention, lipid profiles, liver enzymes, some inflammatory cytokines, and liver fibrosis will be assessed and compared between groups.

Interventions

DIETARY_SUPPLEMENTResveratrol

OTHERplacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Age 18 and older; * Evidence of nonalcoholic steatohepatitis with steatosis grade higher or equal to 1 in ultrasonography; * No history of Alcohol consumption or consuming less than 10 grams alcohol per day in women and less than 20 grams per day in men; * Absence of other liver disorders, malignancies, cardiovascular, respiratory, and kidney disorders; * Absence of pregnancy or lactation; * Absence of taking any medications in the past three months; * Absence of weight loss in the recent three months; * Absence of endocrine and metabolism disorders.

Exclusion criteria

* Weight loss more than 10% of baseline body weight during the intervention period. * Pregnancy; * Disliking to continue the study.

Design outcomes

Primary

Measure	Time frame
Alaninaminotransferase(ALT)	12 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026